We conclude that future therapeutic studies of complex karyotype, TP53 mutated MDS should be of shorter duration, with molecular follow-up after each cycle, and with a more rapid planning to proceed to allo-SCT, if possible. This evidence concerns the gene TP53 and myelodysplastic syndrome.